Exelixis, Inc. (EXEL) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 14.62B USD. 52-week range 33.76 to 61.14 USD. Trailing P/E 18.6. Data as of 2026-10-09.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple ...